The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.
Adverse drug reaction reports worldwide
PFS research studies published
Known suicides worldwide
Doctors & researchers speaking out
Nations warning of PFS
Aug. 4, 2014 Dear Friends: I’m pleased to report that 2014 is shaping up to be a turning point on the road to widespread awareness of post-finasteride syndrome. Couple that with the steady progress of our clinical studies and I become ever more hopeful that the coming year will bring not only worldwide acceptance of […]
SOMERSET, N.J., July 8, 2014 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website rose 26 percent during the first half of 2014, according to Google Analytics. In all, users in 147 countries—or 75 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed […]
SOMERSET, N.J., June 16, 2014 – Post-finasteride syndrome research initiatives at two major U.S. medical institutions, Brigham and Women’s Hospital (a Harvard Medical School Teaching Affiliate) in Boston, Mass., and Baylor College of Medicine in Houston, Texas, are currently recruiting patients for their respective studies on the condition. If you are interested in participating, or […]
April 25, 2014 Dear Friends: The Post-Finasteride Syndrome Foundation is saddened to announce the passing of Daniel M. Stewart. The 37-year-old native of Troy, Michigan, and Centertown, Kentucky, died Saturday, April 12, 2014 at his home in Denton, Texas. Daniel, who suffered from post-finasteride syndrome, had recently taken part in a clinical-research study on the […]
SOMERSET, N.J., Jan. 6, 2014 – The number of nations that logged onto the Post-Finasteride Syndrome Foundation website rose 29 percent in 2013, according to Google Analytics. In all, users in 120 countries outside the United States—or 61 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed […]
Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
—Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020
[A]t least 17 countries…have warned…of the potential for depression, sexual side effects, or both.
Emerging post-marketing reports of persistent depression and sexual side effects have led to growing concerns about the safety of 5α-reductase inhibitors and prompted product labeling changes in many regulatory jurisdictions. Since 2008, at least 17 countries including the United Kingdom and the United States have warned prescribers of the potential for depression, sexual side effects, or both with finasteride.
Two subjects—eight percent—committed suicide during or after the study.
While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.
—Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020
FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.
Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.
—FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000